modelA10BJ05
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Dulaglutide | |
| ATC code: | A10BJ05 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 1.5 | mg |
| volume of distribution: | 19.2 | L |
| clearance: | 0.114 | L/h |
| other parameters in model implementation | ||
Dulaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. It improves glycemic control by enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Dulaglutide is approved and in clinical use.
Pharmacokinetics
Pharmacokinetics in adult type 2 diabetic patients, following repeated subcutaneous administration. Parameters reflect pooled values from both sexes across multiple doses. Population PK analysis, mainly in adults aged 18-75, various ethnic groups.
References
Pratley, RE, et al., & Viljoen, A (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology 6(4) 275–286. DOI:10.1016/S2213-8587(18)30024-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/29397376
Geiser, JS, et al., & de la Peña, A (2016). Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clinical pharmacokinetics 55(5) 625–634. DOI:10.1007/s40262-015-0338-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26507721
Zhang, Q, et al., & Hu, W (2023). Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Expert opinion on biological therapy 23(8) 727–735. DOI:10.1080/14712598.2023.2189009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36880118
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)